Pharmaceutical Company Issues Voluntary Recall Of Methocarbamol Tablets Labeled In Wrong Concentration

The United States Food and Drug Administration (FDA) released the following announcement from Bryant Ranch Prepack regarding a voluntary recall of methocarbamol last week. In horses, injectable methocarbamol is FDA-approved for treatment of “acute inflammatory and traumatic conditions of the skeletal muscle to reduce muscle spasm and effect striated-muscle relaxation.” 

Methocarbamol is also sometimes used off-label orally to manage and treat sore backs and muscle strain. Methocarbamol is also prescribed as a prophylactic for horses that experience exertional rhabdomyolysis or “tying up,” which can cause muscle breakdown. Methocarbamol is a depressant and may affect performance and coordination. 

[Story Continues Below]

Bryant Ranch Prepack is voluntarily recalling one lot of methocarbamol 500 mg tablets to the consumer level. The bottles labeled as methocarbamol 500mg tablets have been found to contain methocarbamol 750 mg Tablets.

Risk Statement: If a patient takes a 750 mg tablet of methocarbamol instead of the prescribed 500 mg tablets, it potentially could result in excessive central nervous system depression, which may result in nausea, sedation, fainting, falls, seizure, coma, and death. Bryant Ranch Prepack has not received any reports of adverse events related to this recall.

The product is used together with rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions and is packaged in a white round bottle with a red and white label, which reads methocarbamol 500 mg packaged in counts of 30 (NDC:7133517952), 60 (NDC: 7133517954), and 90 (NDC:7133517957) pills. The affected methocarbamol 500 mg lots include the following Lot Number 163935/ Exp. Date 10/22. The product can be identified by red and white label with a yellow border at the top and bottom of the label, top of the label reads “Packaged by Bryant Ranch Prepack”, labels are pictured below. The methocarbamol 500 mg was distributed nationwide to multiple physician offices.

Bryant Ranch Prepack is notifying its distributors and customers by letter and email and is arranging for return of all recalled products. Consumers that have the bottles labeled as methocarbamol 500 mg tablets which are being recalled should stop using immediately and return to place of purchase and/or contact their physician. Distributors/physicians should stop distribution and contact Bryant Ranch Prepack to return the product immediately.

Consumers with questions regarding this recall can contact Bryant Ranch Prepack by phone at 877-885-0882 Mon.-Fri. 7am-6pm PST or compliance@brppharma.com. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report online
  • Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

The post Pharmaceutical Company Issues Voluntary Recall Of Methocarbamol Tablets Labeled In Wrong Concentration appeared first on Horse Racing News | Paulick Report.

Source of original post

O’Neill, Miller Combine For Trio Of 4C Drug Rulings Within Past Week

Two-time GI Kentucky Derby-winning trainer Doug O'Neill got fined $2,000 for a pair of methocarbamol positives at Santa Anita Park in May and June, one in a race and the other in a workout.

According to a Sept. 6 ruling published within the California Horse Racing Board (CHRB) weekly stewards' report for Del Mar Thoroughbred Club, the two cases were combined into one because “O'Neill was not aware of the first medication positive [May 30] when the second complaint [June 3] was served by CHRB enforcement.”

Methocarbamol is a Class 4 and Penalty Category C skeletal muscle relaxant. Its 4C categorization is on the least-severe side of the scale on the Uniform Classification Guidelines for Foreign Substances list published by the Association of Racing Commissioners International.

Split-sample testing confirmed the findings. The infraction will also cost O'Neill half a point on the CHRB's multiple medication violations (MMV) penalty list.

O'Neill's attorney, Darrell Vienna, told TDN no appeal is planned.

The violation was O'Neill's second within the last calendar year. In March he negotiated a CHRB settlement agreement that included a $7,500 fine and the serving of 10 days of a 30-day suspension over a 2B positive lidocaine test triggered by one of his trainees in October 2020.

As part of the agreement in that Mar. 6 ruling, the 20 days of that lidocaine suspension were stayed on the condition that O'Neill would not have any Class 1, 2 or 3 violations within a calendar year. So the Class 4 methocarbamol violation does not count against the terms of his agreed-upon probation.

The methocarbamol race violation occurred in Deise Delight (Ire) (Brazen Beau {Aus}), who ran second in a May 30 starter/optional claimer. No disqualification was issued in the ruling, customary to the CHRB's rule about only DQ'ing horses who test for Class 3 or more severe drugs.

The methocarbamol workout violation came on June 3, when O'Neill was attempting to get Team Merchants (Nyquist) cleared from the vet list. The colt won his next start at 18-1 odds on July 16 in a Del Mar optional claimer.

O'Neill is the second prominent trainer within the past week to be handed a penalty for a 4C drug violation in a post-workout test.

On Sept. 2, Peter Miller, the leading trainer at the now-concluded Del Mar meet, was fined $1,500 for a phenylbutazone positive incurred June 19 at San Luis Rey Downs in Mo Forza (Uncle Mo). The MGSW subsequently won his next start, the Aug. 21 GII Del Mar Mile S. as the 11-10 favorite.

Miller was also docked half an MMV point for his second offense within the past year. It was not known at deadline for this story if the ruling will be appealed.

In April, Miller absorbed a $500 fine for a 4C finding of isoflupredone that was confirmed via split-sample testing when his trainee, Hembree (Proud Citizen), won the GII Joe Hernandez S. at Santa Anita Jan. 1.

The post O’Neill, Miller Combine For Trio Of 4C Drug Rulings Within Past Week appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Minimum Fine for Mandella’s 4C Positive in San Simeon

Trainer Richard Mandella has been fined $500 by the California Horse Racing Board (CHRB) for a Class 4 and Penalty Category C methocarbamol positive that turned up in the post-race test of Jolie Olimpica (Brz) (Drosselmeyer) after the MGSW mare ran third in the GIII San Simeon S. at Santa Anita Mar. 13.

The stewards' ruling was issued May 29. According to the original May 7 complaint, split-sample blood testing had confirmed the presence of the skeletal muscle relaxant.

Methocarbamol's 4C categorization is on the least-severe side of the scale on the Uniform Classification Guidelines for Foreign Substances list published by the Association of Racing Commissioners International (ARCI).

Mandella, a Hall-of-Fame conditioner who has been training since 1974, shows three other low-category medication fines of $500 each in the ARCI's rulings database: One for phenylbutazone and flunixin in 2018 at Santa Anita, one for methocarbamol at Santa Anita in 2011, and one for naproxen at Arlington Park in 2007.

In California, a trainer's first violation within a 365-day period for a Category C drug violation can result in a minimum fine of $500 to a maximum fine of $1,000 (absent mitigating circumstances).

CHRB spokesperson Mike Marten confirmed that Mandella paid the fine the day after the ruling was issued.

The post Minimum Fine for Mandella’s 4C Positive in San Simeon appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

4C Methocarbamol Complaint Issued Against Mandella for Graded Stakes Positive

Trainer Richard Mandella has been summoned to a stewards' hearing to answer a California Horse Racing Board (CHRB) complaint of an over-threshold test finding for methocarbamol, a Class 4 and Penalty Category C skeletal muscle relaxant that turned up in the post-race test of Jolie Olimpica (Brz) (Drosselmeyer) after the multiple graded stakes winner ran third in the GIII San Simeon S. at Santa Anita Mar. 13.

According to the May 7 complaint, split-sample blood testing confirmed the presence of the drug.

Methocarbamol's 4C categorization is on the least-severe side of the scale on the Uniform Classification Guidelines for Foreign Substances list published by the Association of Racing Commissioners International (ARCI).

Mandella, a Hall-of-Fame conditioner who has been training since 1974, shows three low-category medication fines of $500 each in the ARCI's rulings database: One for phenylbutazone and flunixin in 2018 at Santa Anita, one for methocarbamol at Santa Anita in 2011, and one for naproxen at Arlington Park in 2007. Fines for two scopolamine positives in 1994 were rescinded after a lengthy investigation.

In California, a trainer's first violation within a 365-day period for a Category C drug violation can result in a minimum fine of $500 to a maximum fine of $1,000 (absent mitigating circumstances).

The post 4C Methocarbamol Complaint Issued Against Mandella for Graded Stakes Positive appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Verified by MonsterInsights